Literature DB >> 3107872

In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.

R J Fass, V L Helsel.   

Abstract

The in vitro activities of RO 23-6240 (AM-833) and four comparative fluoroquinolones were studied. Minimal inhibitory concentrations (MICs) of RO 23-6240, which inhibited at least 90% of strains, were less than or equal to 0.03-1 microgram/ml for Staphylococcus aureus, Staphylococcus epidermidis, Enterobacteriaceae, Acinetobacter anitratus Aeromonas hydrophila, Branhamella catarrhalis, and Haemophilus influenzae, 2-8 micrograms/ml for Staphylococcus saprophyticus, streptococci, diphtheroids, and Pseudomonas spp., and 1-32 micrograms/ml for anaerobic species. MICs of ofloxacin, pefloxacin, norfloxacin, and ciprofloxacin paralleled those of RO 23-6240. With all five drugs, MICs were minimally affected by inoculum size and minimal bacterial concentrations (MBCs) were always within two dilution steps (log2) of MICs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107872     DOI: 10.1016/0732-8893(87)90178-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

Review 1.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

Review 3.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.